Also known as: HPV vaccine
Twenty years after HPV vaccine approval, head and neck cancers have become the most common HPV-related cancer with 16,000 cases annually. The incidence tripled from 2000 to 2017, primarily affecting men in their 40s to 60s. Vaccination rates among teens reached approximately 77-79% for at least one dose in 2024.
Scientists are testing experimental cancer therapies including mRNA therapeutic vaccines, engineered EcN bacteria that deliver romidepsin in mice, and macrophage-targeted CAR T cells.
New research shows HPV vaccination provides sustained protection against invasive cervical cancer for over a decade, with vaccinated individuals showing significantly lower cancer rates. The study found 79% lower risk for those vaccinated before age 17, with protection lasting 13-15 years. Cervical cancer remains a major global health challenge, particularly in regions like India and the Caribbean where infection rates are high.
Australia's National Health and Medical Research Council marks 90 years of funding medical breakthroughs while facing warnings that research institutes could exhaust capital within a decade. The NHMRC's success includes funding the HPV vaccine that put Australia on track to eliminate cervical cancer by 2035, but sustained funding is needed to maintain world-class research capabilities.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07377656 |
Strengthening HPV Immunization Through EPI Leveraged Delivery |
RECRUITING | PHASE2 |
| NCT05291871 |
Immunogenicity of Fractional Dose of the HPV Vaccines |
ACTIVE_NOT_RECRUITING | PHASE4 |
| NCT04235257 |
Intradermal, Fractional Dose of HPV Vaccines: |
ACTIVE_NOT_RECRUITING | PHASE4 |
